Oscotec
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
OSCOTECInc is a South Korean biotech company, listed on KOSDAQ, that develops synthetic small-molecule drugs for conditions such as arthritis and cancer, while also supplying functional health-food ingredients and dental bone-graft materials used in dental procedures.
Its products reach domestic pharmaceutical companies, dentists, and health-food manufacturers. The business runs three parallel lines, drug discovery, functional ingredients, and dental bone grafts, with a targeted lung-cancer compound that has been approved by both the Korean drug regulator and the US FDA as a first-line treatment, either alone or in combination.
Summary is AI-generated and may contain errors · figures from DART filings
The lung-cancer compound was licensed out to a domestic pharmaceutical company through a technology-transfer agreement, making licensing a key part of its drug-development model.
Oscotec in five facts
What does Oscotec do?
OSCOTECInc is a South Korean biotech company, listed on KOSDAQ, that develops synthetic small-molecule drugs for conditions such as arthritis and cancer, while also supplying functional health-food ingredients and dental bone-graft materials used in dental procedures.
Where is Oscotec listed and in which sector?
Oscotec (Korean name: 오스코텍) trades under KRX code 039200 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Oscotec?
Its market capitalisation was US$1.1B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Oscotec's latest annual revenue and operating profit?
For fiscal year 2025, Oscotec reported revenue of US$75.4M, operating profit of US$39.3M and net income of US$41.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 193.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Shareholder register closure / record date setOct 6
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 6
- DisclosureSep 23
- [Amended] Report on large shareholdings (5% rule) (standard)Sep 18
- Report on large shareholdings (5% rule) (standard)Sep 17
- Report on large shareholdings (5% rule) (abbreviated)Sep 17
- DisclosureSep 4
- Report on large shareholdings (5% rule) (standard)Sep 1
- [Amended] Change of largest shareholder
Oscotec amended its February 5, 2026 report on a change of largest shareholder due to inheritance, confirming that the inheritance division agreement was completed on July 15, 2026 and the new largest shareholder is Kim Seong-yeon and one other, holding 4,765,055 shares (12.45%).
Ownership change · Jul 23 · 2 versions - Share-pledge agreement that may change the largest shareholder
Oscotec's largest shareholder pledged shares as loan collateral, securing up to US$82.3M.
Ownership change · Jul 23 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Oscotec reported consolidated results for FY2025: revenue of US$69.7M (+193.5% year on year), operating profit of US$36.4M (from a loss a year earlier) and net income of US$38.2M (from a loss a year earlier).
Earnings · Feb 27